3 Hard Facts Moderna and Pfizer Investors Need to Know About the Omicron Variant
As the leading coronavirus vaccine makers in the U.S., Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) will once again be put to the test by a new viral variant. So far, the market hasn't reacted favorably to comments by Moderna's CEO, Stéphane Bancel, who on Nov. 30 echoed to the Financial Times other scientists' thoughts that "this is not going to be good," regarding the prospects for the continued efficacy of the company's vaccine against the variant.
Bancel's opinion isn't the only thing that investors need to be aware of when it comes to the new variant, though. In particular, there are three facts that will influence how Pfizer and Moderna's stocks perform in light of omicron -- and they aren't all pretty.
Image source: Getty Images
Source Fool.com
